TARSUS PHARMACEUTICALS, INC.
Last · NASDAQ$72.29+1.47 (+2.08%)close · yahoo · 8h ago
Market cap$3.38B46.8M sh
P/E · TTM-66.9fwd -263 · eps -1.08 · loss
Beta0.45vs S&P 500
Div yield0.00%annual · TTM
52w range
$53.89$91.53
Volume747.7Ksession
| Revenue | $606.3M |
|---|---|
| Operating income | $-26.0M |
| Net income | $-25.5M |
| Free cash flow | $26.7M |
| Operating margin | -4.3% |
| Net margin | -4.2% |
| Return on equity | -7.4% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-23
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Accumulated Deficit High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -14.7%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -2.8%
- Accumulated Deficit High — Accumulated deficit / equity 124%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$1.69
Est. revenue
186.3M
Earnings transcripts
Press & signals
- GlobeNewswire
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
- GlobeNewswire
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
- GlobeNewswire
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans